Gilead Sciences (GILD) Declares $0.52 Quarterly Dividend; 2.7% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Gilead Sciences (GILD) Tops Q3 EPS by 14c
October 26, 2017 4:04 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.27, $0.14 better than the analyst estimate of $2.13. Revenue for the quarter came in at $6.51 billion versus the consensus estimate of $6.39 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
... MoreGilead Sciences (GILD) Announces Phase 2 Results for GS-0976 in NASH
October 24, 2017 8:37 AM EDTGilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH). The data demonstrate that the higher dose of GS-0976 (20 mg taken orally once daily) when administered for 12 weeks was associated with statistically significant reductions in hepatic steatosis (buildup of fat in the liver) and a noninvasive marker of fibrosis (TIMP-1) compared to placebo. These results are being presented during a late-breaking abstract session at The Liver Meeting® 2017 in... More
